Efficacy of botulinum toxin in masseter muscle hypertrophy for lower face contouring.
Botulinum toxin type A
lower face contouring
masseter botox
masseter muscle
masseter muscle hypertrophy
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
03
11
2021
accepted:
14
02
2022
pubmed:
18
2
2022
medline:
25
5
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Masseter muscle hypertrophy (MMH) usually presents with cosmetic concerns as it may lead to widening of the lower face. Apart from the traditional surgical approaches, botulinum toxin type A (BTA) injection is a non-invasive treatment option available. There are no standard guidelines for this procedure. To study the efficacy of botulinumtoxin A in MMH for lower face contouring. The Cochrane Library, PubMed/MEDLINE, Google-scholar, Science-Direct database, and ResearchGate from inception until September 2021 were searched using the keywords "botulinumtoxin type A," "masseter muscle hypertrophy," "lower face contouring," and "masseter botox." All available retrospective and prospective studies, case-series, case-reports, and expert reviews were included with an emphasis on efficacy of BTA in MMH and units injected into the muscle, points of placement, adverse events, and the duration of its effect. Reference lists of the resultant articles, as well as relevant reviews, were also searched. 40 articles were shortlisted for the review, of which 14 studies with sample-size ≥10 in accordance with the study requirements were summarized in a tabular form for analysis and easy comparison and reference. BTA injection is a non-invasive, safe, and effective treatment for MMH. The optimum number of BTA units could not be ascertained due to wide variability in the studies as well as ethnicity of patients and extent or some measurement of MMH. The points of placement of injection should be well within the boundaries of the masseter muscle. The maximum effect of BTA after a single injection session is usually seen in ~3 months, and the duration may last for 6-12 months. Multiple injection sessions may be required to maintain a long-term effect. Injection technique and total number of injection units of neuromodulator must be individualized for each patient.
Sections du résumé
BACKGROUND
BACKGROUND
Masseter muscle hypertrophy (MMH) usually presents with cosmetic concerns as it may lead to widening of the lower face. Apart from the traditional surgical approaches, botulinum toxin type A (BTA) injection is a non-invasive treatment option available. There are no standard guidelines for this procedure.
OBJECTIVES
OBJECTIVE
To study the efficacy of botulinumtoxin A in MMH for lower face contouring.
METHODOLOGY
METHODS
The Cochrane Library, PubMed/MEDLINE, Google-scholar, Science-Direct database, and ResearchGate from inception until September 2021 were searched using the keywords "botulinumtoxin type A," "masseter muscle hypertrophy," "lower face contouring," and "masseter botox." All available retrospective and prospective studies, case-series, case-reports, and expert reviews were included with an emphasis on efficacy of BTA in MMH and units injected into the muscle, points of placement, adverse events, and the duration of its effect. Reference lists of the resultant articles, as well as relevant reviews, were also searched.
RESULT
RESULTS
40 articles were shortlisted for the review, of which 14 studies with sample-size ≥10 in accordance with the study requirements were summarized in a tabular form for analysis and easy comparison and reference.
CONCLUSION
CONCLUSIONS
BTA injection is a non-invasive, safe, and effective treatment for MMH. The optimum number of BTA units could not be ascertained due to wide variability in the studies as well as ethnicity of patients and extent or some measurement of MMH. The points of placement of injection should be well within the boundaries of the masseter muscle. The maximum effect of BTA after a single injection session is usually seen in ~3 months, and the duration may last for 6-12 months. Multiple injection sessions may be required to maintain a long-term effect. Injection technique and total number of injection units of neuromodulator must be individualized for each patient.
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1849-1856Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Cheng J, Hsu SH, McGee JS. Botulinum toxin injections for masseter reduction in East Asians. Dermatol Surg. 2019;45:566-572.
Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115:919-930.
Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodelling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 2014;89:878-884.
Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003;29:477-483.
Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55:8.
Chang CS, Bergeron L, Yu CC, Chen PK, Chen YR. Mandible changes evaluated by computed tomography following Botulinum Toxin A injections in square-faced patients. Aesthetic Plast Surg. 2011;35:452-455.
Wu WT. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width. Facial Plast Surg Clin North Am. 2010;18:133-140.
Peng H-LP, Hypertrophy M. Toxin treatment techniques, causes of complications, and prevention. Botulinum Toxin. 2018;1:73-81.
Vashi NA, de Castro Maymone MB, Kundu RV. Aging differences in ethnic skin. J Clin Aesthet Dermatol. 2016;9:31-38.
Corcoran NM, Goldman EM. Anatomy, head and neck, masseter muscle. In: StatPearls [Internet]. StatPearls Publishing; 2022.
Legg JW. Enlargement of the temporal and masseter muscles on both sides. Trans Pathol Soc (Lond). 1880;31:361-366.
Rispoli DZ, Camargo PM, Pires JL Jr, Fonseca VR, Mandelli KK, Pereira MA. Benign masseter muscle hypertrophy. Braz J Otorhinolar. 2008;74:790-793.
Ayhan M, Isler SC, Kasapoglu C. Combination of medical and surgical treatments for masseter hypertrophy. Case Rep Dentistr. 2018;2018:1-5.
Gurney CE. Chronic bilateral benign hypertrophy of the masseter muscle. Am J Surg. 1947;73:137.
Beckers HL. Masseteric muscle hypertrophy and its intraoral surgical correction. J Maxillofac Surg. 1977;5:28-35.
Ham JW. Masseter muscle reduction procedure with radiofrequency coagulation. J Oral Maxillofac Surg. 2009;67:457-463.
Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg. 1994;32:29-33.
Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. 1994;32:26-28.
Almukhtar RM, Fabi SG. The masseter muscle and its role in facial contouring, aging, and quality of life: a literature review. Plast Reconstr Surg. 2019;143:39e-48e.
Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125:1693-1705.
Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29:484-489.
Bae JH, Choi DY, Lee JG, Seo KK, Tansatit T, Kim HJ. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg. 2014;40:1334-1339.
Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral Maxillofac Surg. 1999;57:1017-1019.
Von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107:327-332.
Cha YR, Kim YG, Kim JH, Kim ST. Effect of unilateral injection of botulinum toxin on lower facial asymmetry as evaluated using three-dimensional laser scanning. Dermatol Surg. 2013;39:900-906.
Shim WH, Yoon SH, Park JH, Choi Y-C, Kim ST. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan. Dermatol Surg. 2010;36:2161-2166.
Wei J, Xu H, Dong J, Li Q, Dai C. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type A injection. Dermatol Surg. 2015;41:S101-S109.
Quezada-Gaon N, Wortsman X, Peñaloza O, Carrasco JE. Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects. J Cosmet Dermatol. 2016;15:238-244.
Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Plast Reconstr Surg. 2014;134:209e-e218.
Shome D, Khare S, Kapoor R. Efficacy of botulinum toxin in treating Asian Indian patients with masseter hypertrophy: a 4-year follow-up study. Plast Reconstr Surg. 2019;144:390e-e396.
Shome D, Vadera S, Shiva Ram M, Kapoor R. Efficacy of Incobotulinum toxin-A for the treatment of masseter muscle hypertrophy in Asian Indian patients: a 2-year follow-up study. J Cosmet Dermatol. 2020;19:1892-1899.
Hong JY, Jeong GJ, Kwon TR, Kim JH, Li K, Kim BJ. Efficacy and safety of a novel botulinum toxin a for masseter reduction: a randomized, double-blind, placebo-controlled, optimal dose-finding study. Dermatol Surg. 2021;47:e5-9.
Lee HJ, Jung SJ, Kim ST, Kim HJ. Ultrasonographic considerations for safe and efficient botulinum neurotoxin injection in masseteric hypertrophy. Toxins. 2021;13:28.
Bae H, Kim J, Seo KK, Hu KS, Kim ST, Kim HJ. Comparison between conventional blind injections and ultrasound-guided injections of botulinum toxin type A into the masseter: a clinical trial. Toxins. 2020;12:588.
Zheng Z, Hao Y, Yin J, Lei X, Cheng B, Huang W. Autogenous fat transplantation and botulinum toxin injection into the masseter muscle to create an ideal oval face. Aesthet Surg J. 2021;41(6):NP579-NP588.
Nikolis A, Enright KM, Rudolph C, Cotofana S. Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A. J Cosmet Dermatol. 2020;19:1294-1300.
Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J. 2008;28:251-257.
Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31:502-507.
Kim JH, Shin JH, Kim ST, Kim CY. Effects of two different units of botulinum toxin type A evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg. 2007;119:711-717.